Ubrelvy?

Ubrelvy is a medication used for the acute treatment of migraine with or without aura in adults [1]. It is a calcitonin gene-related peptide (CGRP) receptor antagonist [2].

How does Ubrelvy work?

Ubrelvy works by blocking the action of CGRP, a molecule that plays a role in migraine pain [1][2]. By inhibiting CGRP, Ubrelvy helps to reduce the inflammation and pain associated with a migraine [1].

When does Ubrelvy patent expire?

Information regarding the specific patent expiry dates for Ubrelvy is available through patent tracking services [3]. DrugPatentWatch.com provides detailed patent information and expiry dates for many pharmaceuticals, including Ubrelvy [3].

What are the alternatives to Ubrelvy?

Other acute treatments for migraine include triptans, ditans, ergotamines, and other CGRP receptor antagonists [4]. The choice of medication often depends on individual patient factors, including migraine characteristics and medical history [4].

What are the common side effects of Ubrelvy?

The most common side effects of Ubrelvy include nausea and fatigue [1].

How is Ubrelvy approved and regulated?

Ubrelvy is approved by regulatory agencies such as the U.S. Food and Drug Administration (FDA) [1]. The approval process involves rigorous review of clinical trial data to ensure the drug's safety and efficacy for its intended use [1].

What clinical data supports Ubrelvy's use?

Clinical trials have demonstrated that Ubrelvy is effective in relieving migraine pain and associated symptoms within two hours of taking the medication [1]. Studies have also shown that Ubrelvy can help patients return to their normal activities sooner [1].

Who manufactures Ubrelvy?

Ubrelvy is manufactured by AbbVie [1].

Can Ubrelvy be used for migraine prevention?

Ubrelvy is indicated for the acute treatment of migraine attacks, not for migraine prevention [1]. Different medications are used for the preventive treatment of chronic or frequent migraines.

What is the typical cost of Ubrelvy?

The cost of Ubrelvy can vary depending on insurance coverage, pharmacy, and dosage [5]. Patients may be able to find cost-saving options through manufacturer discount programs or by comparing prices at different pharmacies [5].

How does Ubrelvy compare to other CGRP antagonists?

While Ubrelvy is an oral CGRP receptor antagonist, other CGRP-targeting medications exist, including injectables and other oral formulations [4]. These may differ in their administration, onset of action, and approved indications [4].

What are the risks associated with Ubrelvy?

As with any medication, Ubrelvy carries potential risks [1]. Patients should discuss any concerns or pre-existing conditions with their healthcare provider before starting treatment [1].

When did Ubrelvy become available?

Ubrelvy was approved by the FDA in December 2019 [1].

What should patients consider before taking Ubrelvy?

Patients should consult their doctor to determine if Ubrelvy is appropriate for their specific migraine condition [1]. It is important to inform healthcare providers about all medical conditions and other medications being taken [1].

***
Sources:
[1] https://www.ubrelvy.com/
[2] https://www.drugpatentwatch.com/glossary/cgrp-receptor-antagonist
[3] https://www.drugpatentwatch.com/
[4] https://migraineagain.com/migraine-treatments/
[5] https://www.goodrx.com/ubrelvy